Institution
Nova Southeastern University
Education•Fort Lauderdale, Florida, United States•
About: Nova Southeastern University is a education organization based out in Fort Lauderdale, Florida, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 6668 authors who have published 11018 publications receiving 344391 citations. The organization is also known as: Nova & NSU.
Papers published on a yearly basis
Papers
More filters
Christopher J L Murray1, Ryan M Barber, Kyle J Foreman2, Ayse Abbasoglu Ozgoren +608 more•Institutions (251)
TL;DR: Patterns of the epidemiological transition with a composite indicator of sociodemographic status, which was constructed from income per person, average years of schooling after age 15 years, and the total fertility rate and mean age of the population, were quantified.
1,609 citations
Nicholas J Kassebaum1, Megha Arora1, Ryan M Barber1, Zulfiqar A Bhutta2 +679 more•Institutions (268)
TL;DR: In this paper, the authors used the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2015.
1,533 citations
Anglia Ruskin University1, University of Oxford2, Heidelberg University3, L V Prasad Eye Institute4, Massachusetts Eye and Ear Infirmary5, Nova Southeastern University6, Brien Holden Vision Institute7, University of KwaZulu-Natal8, Flinders University9, University of New South Wales10, Royal Liverpool University Hospital11, World Health Organization12, National University of Singapore13, University of Melbourne14, Selçuk University15, University of Burgundy16, University of Miami17, University of Adelaide18, Queen's University Belfast19, Harvard University20, The George Institute for Global Health21, University of Washington22, University of Michigan23, Universiti Tunku Abdul Rahman24, University of Alabama25, National Institutes of Health26, Johns Hopkins University27, University of São Paulo28, Henry Ford Health System29, University College London30, University of Nairobi31, University of Georgia32, University of Utah33, Federal University of São Paulo34, Yale University35, Alberta Children's Hospital36, University of Pennsylvania37, Medical College of Wisconsin38, Novartis39, University of Udine40, University of Illinois at Urbana–Champaign41, Royal Children's Hospital42, University of Missouri43, University of Milan44, Centers for Disease Control and Prevention45, Singapore National Eye Center46, Icahn School of Medicine at Mount Sinai47, Mayo Clinic48, Pan American Health Organization49, University of Indonesia50, University of Crete51, Erasmus University Rotterdam52, University of Southern California53, University of Florence54, Stellenbosch University55, Capital Medical University56, Leipzig University57, Moorfields Eye Hospital58
TL;DR: There is an ongoing reduction in the age-standardised prevalence of blindness and visual impairment, yet the growth and ageing of the world's population is causing a substantial increase in number of people affected, highlighting the need to scale up vision impairment alleviation efforts at all levels.
1,473 citations
Anglia Ruskin University1, Norwegian Institute of Public Health2, University of London3, Carnegie Mellon University4, Heidelberg University5, L V Prasad Eye Institute6, Nova Southeastern University7, Brien Holden Vision Institute8, University of KwaZulu-Natal9, Flinders University10, University of Melbourne11
TL;DR: The differences and temporal changes found in causes of blindness and MSVI have implications for planning and resource allocation in eye care.
1,388 citations
University of Oslo1, Saarland University2, University of Hull3, Nova Southeastern University4, University of Copenhagen5, University of Gothenburg6, Charles University in Prague7, University of Helsinki8, University of Geneva9, Katholieke Universiteit Leuven10, University of Groningen11, AstraZeneca12
TL;DR: Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the numberOf cardiovascular hospitalizations and the drugdid not cause safety problems.
Abstract: As compared with the placebo group, patients in the rosuvastatin group had de- creased levels of low-density lipoprotein cholesterol (difference between groups, 45.0%; P<0.001) and of high-sensitivity C-reactive protein (difference between groups, 37.1%; P<0.001). During a median follow-up of 32.8 months, the primary outcome occurred in 692 patients in the rosuvastatin group and 732 in the placebo group (hazard ratio, 0.92; 95% confidence interval (CI), 0.83 to 1.02; P = 0.12), and 728 patients and 759 patients, respectively, died (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P = 0.31). There were no significant differences between the two groups in the coronary outcome or death from cardiovascular causes. In a prespecified secondary analysis, there were fewer hospitalizations for cardiovascular causes in the rosuvastatin group (2193) than in the placebo group (2564) (P<0.001). No excessive episodes of muscle-related or other adverse events occurred in the rosuvastatin group. Conclusions Rosuvastatin did not reduce the primary outcome or the number of deaths from any cause in older patients with systolic heart failure, although the drug did reduce the number of cardiovascular hospitalizations. The drug did not cause safety problems. (ClinicalTrials.gov number, NCT00206310.)
1,355 citations
Authors
Showing all 6722 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Jasvinder A. Singh | 176 | 2382 | 223370 |
| John D. Minna | 169 | 951 | 106363 |
| Yang Gao | 168 | 2047 | 146301 |
| Stephen J. O'Brien | 153 | 1062 | 93025 |
| Carlos Escobar | 148 | 1184 | 95346 |
| David Price | 138 | 1687 | 93535 |
| António Amorim | 136 | 1477 | 96519 |
| James Mueller | 134 | 1194 | 87738 |
| Peter R Hobson | 133 | 1590 | 94257 |
| J. Boudreau | 132 | 1606 | 114745 |
| Marzio Nessi | 129 | 1046 | 78641 |
| Riccardo-Maria Bianchi | 126 | 870 | 73816 |
| Alan E. Kazdin | 125 | 498 | 64161 |
| Johannes Erdmann | 122 | 732 | 66864 |
| Harinder Singh Bawa | 120 | 798 | 66120 |